Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy

Inclusion Criteria: * HIV-1 infected * Stable ART containing zidovudine or stavudine for at least 12 consecutive weeks prior to study entry * Cumulative ART with zidovudine or stavudine for at least 24 weeks prior to study entry * Viral load of 5,000 copies/ml or less within 45 days prior to study entry * Lipoatrophy in at least two of the following areas: face, arms, legs, OR buttocks * Not planning to add to or change current vitamin supplementation * Willing to use acceptable forms of contraception Exclusion Criteria: * Life expectancy of less than 12 months * Currently enrolled in or planning to enroll in an ART interruption study * Plans to change current ART regimen * Liver failure at anytime prior to study entry * Greater than Grade 2 diarrhea or vomiting within 7 days prior to study entry * Current AIDS-defining opportunistic infection or illness. Individuals with cutaneous Kaposi's sarcoma not requiring chemotherapy are not excluded. * Currently receiving insulin or oral hypoglycemic products for diabetes mellitus * Systemic cancer chemotherapy or immunomodulating agents within 30 days prior to study entry * Systemic steroids for a cumulative duration of longer than 4 weeks within the 6 months prior to study entry * Known allergy or sensitivity to study drug or any of its components * Severe lactose intolerance * Current drug or alcohol abuse or dependence * Clinically significant illness requiring systemic treatment or hospitalization * Chronic disability or seri…